With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly’s heels

Published on:

The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being “interchangeable” with Lilly’s Retevmo, which received accelerated FDA approval last week.

Read more    Source:

Leave a Reply